History

Before recombinant production, growth hormone was extracted from human cadaver pituitaries. In 1985 the FDA halted distribution of cadaver-derived GH after recipients developed fatal iatrogenic Creutzfeldt-Jakob disease (CJD) from prion-contaminated material — at least 226 cases worldwide (29 in the US) have been linked to it, with long-latency cases still reported. The first recombinant GH, Genentech's Protropin, was FDA-approved in 1985; its active ingredient was somatrem, a 192-amino-acid methionyl analogue. The first true native-sequence somatropin (191-amino-acid), Eli Lilly's Humatrope, was approved in 1987, followed by numerous brands.

Somatropin is recombinant human growth hormone (rhGH), the lab-made version of the hormone the pituitary gland produces naturally. It is a protein hormone — not an anabolic steroid and not a small-molecule “research chemical” — and it is a legitimately FDA-approved medicine for several conditions. Outside those medical uses, it is heavily marketed for anti-aging, fat loss, and athletic performance, where the best controlled evidence is far weaker than its reputation, and where non-medical distribution is a federal felony.

What it is

Somatropin is a single-chain 191-amino-acid polypeptide (~22 kDa) with a sequence identical to the dominant form of endogenous pituitary growth hormone. It is produced in genetically engineered host cells (commonly E. coli; some products use mammalian cells). An early related product, somatrem (Protropin), was a 192-amino-acid methionyl variant.

Because it is a protein hormone, somatropin is given by subcutaneous (or intramuscular) injection. It is not orally bioavailable as an intact protein — it would be digested — so there is no legitimate oral HGH, and the “oral vs. injectable ester” framing that applies to anabolic steroids does not apply here at all. Somatropin is not an androgen receptor agonist, is not 17-alpha-alkylated, and is not an anabolic steroid under US law.

Mechanistically, GH binds the transmembrane growth hormone receptor (GHR), a cytokine-receptor family member, triggering JAK2/STAT5 signaling. Many of its anabolic and growth effects are mediated indirectly through hepatic and local production of insulin-like growth factor 1 (IGF-1). GH also has direct effects: lipolysis (fat breakdown), fluid retention, and an anti-insulin (diabetogenic) effect on glucose metabolism. It promotes protein synthesis, linear bone growth where growth plates are still open, and lipid, carbohydrate, and mineral metabolism.

The claims

GH has genuine, FDA-approved medical indications. In children: GH deficiency, Turner syndrome, Prader-Willi syndrome, Noonan syndrome, SHOX deficiency, chronic renal insufficiency/pre-transplant, small-for-gestational-age with failure to catch up, and idiopathic short stature. In adults: adult GH deficiency, HIV-associated wasting/cachexia (brand Serostim), and short bowel syndrome (brand Zorbtive, FDA-approved for this use though since discontinued in marketing).

Separately, GH is promoted — without approval — for anti-aging and “wellness,” body recomposition (more muscle, less fat), and athletic or strength performance. None of these are approved uses, and the evidence for them is weak.

What the evidence actually shows

True GH deficiency (children and adults): robust, well-established benefit. Increased linear growth in deficient children, and improved body composition, bone density, and quality-of-life measures in deficient adults. This is the core, evidence-supported use and the reason the drug exists.

Body composition in healthy/older adults: The landmark Rudman et al. trial (NEJM, 1990; 21 men aged 61-81, 12 treated and 9 controls, over 6 months) found GH increased lean body mass by about 8.8% and decreased adipose-tissue mass by about 14.4% — a result that launched the modern “anti-aging GH” industry. Crucially, that trial did not measure or demonstrate any functional or strength gains, and later work showed the body-composition shift does not translate into meaningful strength or function.

Systematic-review evidence in the healthy elderly: Liu et al. (Annals of Internal Medicine, 2007; ~220 participants, mean age ~69) found GH produced only small reductions in fat mass and small increases in lean mass — roughly 2 kg each, with no net weight change — and no proven improvement in strength, aerobic capacity, or other clinically meaningful outcomes, alongside significantly increased adverse events (soft-tissue edema, joint pain, carpal tunnel syndrome, gynecomastia, and higher rates of impaired fasting glucose/diabetes). The authors concluded GH cannot be recommended as an anti-aging therapy.

Athletes and strength: Much of the “lean mass” increase from GH is fluid retention (extracellular water), not contractile muscle. Controlled data do not support improvements in muscle strength, power, or sport-relevant performance in healthy or athletic adults; aerobic capacity may not improve, and edema and fatigue can make it worse. The performance reputation of GH substantially outpaces the evidence.

Legal and regulatory status

HGH is not a controlled substance under the Controlled Substances Act, and it is not an anabolic steroid (anabolic steroids are Schedule III under the Anabolic Steroid Control Act — a separate category that does not include GH).

Instead, HGH has its own dedicated criminal statute: 21 U.S.C. § 333(e). It is a felony to knowingly distribute, or possess with intent to distribute, HGH for any use in humans other than the treatment of a disease or recognized medical condition authorized by the Secretary of HHS and ordered by a physician. The statute defines “human growth hormone” as somatrem, somatropin, or an analogue of either. Distribution for anti-aging, athletic performance, or bodybuilding is therefore illegal. Penalties run up to 5 years imprisonment (up to 10 years if the offense involves a person under 18). A conviction is treated as a felony violation of the Controlled Substances Act for forfeiture purposes, and the DEA is authorized to investigate such offenses.

In sport, growth hormone is prohibited at all times — in and out of competition — under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). S2 also covers IGF-1, EPO/ESAs, GH-releasing peptides and secretagogues (such as the GHRPs, ipamorelin, CJC-1295, and MK-677), and GH fragments such as AOD-9604. This is unchanged on the 2026 Prohibited List, in force since January 1, 2026. (Anabolic agents are S1, not S2 — a common point of confusion; GH and its related growth factors sit in S2.)

Safety

GH-specific risks are different from anabolic-steroid risks. Several harms commonly attributed to “performance drugs” — liver injury from 17-alpha-alkylation, suppression of the testosterone axis, virilization, androgenic gynecomastia, and polycythemia — are anabolic-steroid effects and do not apply to GH. They are noted here only to keep the picture honest.

Fluid retention and edema, joint pain (arthralgias), muscle pain (myalgias), and carpal tunnel syndrome — the most common, dose-related adverse effects.
Glucose metabolism: GH is diabetogenic. It causes insulin resistance and can produce impaired fasting glucose or new-onset type 2 diabetes — a meaningful concern in older or at-risk people.
Acromegaly-like features with chronic excess or supraphysiologic use: soft-tissue and bony overgrowth (hands, feet, jaw, facial coarsening), organomegaly, and cardiac hypertrophy/cardiomyopathy.
Cardiovascular: acromegaly and chronic GH excess are associated with cardiac hypertrophy, hypertension, and increased cardiovascular morbidity. GH-excess effects center on cardiac structure and glucose/metabolic changes rather than the lipid shifts seen with oral anabolic steroids.
Cancer/mortality signals: GH stimulates IGF-1, which raises a theoretical concern about tumor promotion. The FDA issued a Drug Safety Communication in 2010 reviewing a possible mortality signal in the French SAGhE data (childhood-treated short-stature patients), then an August 2011 update concluding the evidence was inconclusive owing to study-design limitations and the absence of a corroborating signal elsewhere. The concern warrants caution, especially with non-medical use.
Pediatric-specific risks: intracranial hypertension, slipped capital femoral epiphysis, and scoliosis progression. GH is contraindicated in active malignancy, in certain Prader-Willi patients with severe obesity or respiratory impairment (deaths reported), and in acute critical illness (increased mortality shown in ICU trials).
Prion risk is historical and applies to cadaver-derived GH, not recombinant somatropin.
Black-market product risk: counterfeit or unregulated “HGH” is frequently underdosed, mislabeled, or non-sterile, adding infection and contaminant risk on top of everything above.

Bottom line

Somatropin is a legitimately FDA-approved recombinant growth hormone with strong evidence in true GH deficiency and specific pediatric and wasting indications. For healthy adults, older people, and athletes, the best controlled evidence (Liu 2007, plus the functional null in Rudman-era and later work) shows only small body-composition changes, no proven functional, strength, or performance benefit, and a meaningful adverse-event burden. Non-medical distribution is a federal felony under 21 U.S.C. § 333(e), and GH is banned at all times in sport under WADA S2.

Evidence grade: Strong human.

This grade reflects the quality of the underlying human evidence — which is strong on both counts: strong support for benefit in genuine GH deficiency and the approved medical conditions, and strong, well-controlled evidence that the popular anti-aging and performance uses do not deliver meaningful functional benefit.

Somatropin (HGH)